![Martin Roelsgaard Jakobsen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Oorsprong van het eerstegraads netwerk van Martin Roelsgaard Jakobsen
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
STipe Therapeutics ApS
![]() STipe Therapeutics ApS Pharmaceuticals: MajorHealth Technology STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark.
8
| Holding Company | Pharmaceuticals: Major | 8 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Martin Roelsgaard Jakobsen via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
Onyx Pharmaceuticals, Inc.
![]() Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
EXELIXIS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Coley Pharmaceutical Group, Inc.
![]() Coley Pharmaceutical Group, Inc. Pharmaceuticals: MajorHealth Technology Coley Pharmaceutical Group, Inc. manufactures drugs to treat chronic diseases. The company discovers and develops receptors therapeutic candidates for cancers, asthma, and allergic disorders. It was founded in 1997 and is headquartered in Wellesley, MA | Pharmaceuticals: Major | Corporate Officer/Principal | |
Zymeworks BC, Inc.
![]() Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Biotechnology | Director/Board Member | |
AURA BIOSCIENCES, INC. | Biotechnology | Director/Board Member | |
CARIBOU BIOSCIENCES, INC. | Biotechnology | Director/Board Member | |
MEDIVIR AB | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
University of Oxford | College/University | Doctorate Degree Undergraduate Degree | |
Imperial College London | College/University | Masters Business Admin | |
University of Cambridge | College/University | Graduate Degree | |
Danmarks Eksport- og Investeringsfond
![]() Danmarks Eksport- og Investeringsfond Investment ManagersFinance Danmarks Eksport- og Investeringsfond (EIFO) is a venture capital subsidiary of Government of Denmark and founded in 1992. The firm is headquartered in Hellerup, Denmark. | Investment Managers | Private Equity Investor | |
Bryn Mawr College | College/University | Undergraduate Degree | |
Universität zu Köln | College/University | Doctorate Degree | |
The University of California, San Francisco | College/University | Corporate Officer/Principal | |
University of Aarhus | College/University | Doctorate Degree | |
University College London | College/University | Doctorate Degree | |
Molecular Vision Ltd.
![]() Molecular Vision Ltd. Medical SpecialtiesHealth Technology Molecular Vision Ltd. develops low-cost, lab-quality, point of care, disposable diagnostic devices for medical testing. The company was founded by Donal D. C. Bradley in 2001 and is headquartered in York, the United Kingdom. | Medical Specialties | Director/Board Member | |
Brandon Capital Partners Pty Ltd.
![]() Brandon Capital Partners Pty Ltd. Investment ManagersFinance Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia. | Investment Managers | Director/Board Member | |
Coley Pharmaceutical GmbH
![]() Coley Pharmaceutical GmbH Miscellaneous Commercial ServicesCommercial Services Part of Pfizer Inc., Coley Pharmaceutical GmbH is a German company that provides research and development in the field of natural sciences, engineering, agricultural sciences and medicine. The company is based in Berlin, Germany. The company was founded by Heather L. Davis. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
BIO Deutschland
![]() BIO Deutschland Miscellaneous Commercial ServicesCommercial Services BIO Deutschland is a business association for the biotechnology industry. The private company is based in Berlin, Germany. The German company was founded by Peter Heinrich, Horst Domdey. Viola Bronsema has been the CEO of the company since 2006. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Harvard T.H. Chan School of Public Health | College/University | Graduate Degree | |
KAROLINSKA DEVELOPMENT AB | Financial Conglomerates | Chief Executive Officer | |
Pcovery ApS
![]() Pcovery ApS Pharmaceuticals: MajorHealth Technology Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Founder | |
ABINGDON HEALTH PLC | Medical Specialties | Private Equity Investor | |
Boehringer Ingelheim (Canada) Ltd.
![]() Boehringer Ingelheim (Canada) Ltd. BiotechnologyHealth Technology Boehringer Ingelheim (Canada) Ltd. engages in the research and development of new drugs and medicines for the treatment of respiratory diseases. The firm offers therapeutic options for diseases and conditions, such as chronic obstructive pulmonary disease, high blood pressure, stroke, depression, benign prostatic hyperplasia, Parkinson's disease, virology, stroke prevention in atrial fibrillation, and diabetes. The company was founded in 1972 and is headquartered in Burlington, Canada. | Biotechnology | Corporate Officer/Principal | |
Perelman School of Medicine | College/University | Doctorate Degree | |
OMEICOS Therapeutics GmbH
![]() OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | Biotechnology | Director/Board Member | |
Rigontec GmbH
![]() Rigontec GmbH Pharmaceuticals: MajorHealth Technology Rigontec GmbH provides RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The firm develops a compound stimulating the immune receptor retinoic acid-inducible gene. The company was founded by Annegret de Baey-Diepolder, Gunther Hartmann, Anna Schwickart, Marcel Renn, Christine Schuberth-Wagner and Veit Hornung in 2014 and is headquartered in Munich, Germany. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Executive Officer | |
TRiCares SAS
![]() TRiCares SAS Medical SpecialtiesHealth Technology Tricares SAS commercializes medical device. The company was founded by Coralie Marchand and Pascal Lim on September 2, 2013 and is headquartered in Paris, France. | Medical Specialties | Director/Board Member | |
Svenska Vaccinfabriken Produktion AB
![]() Svenska Vaccinfabriken Produktion AB BiotechnologyHealth Technology Svenska Vaccinfabriken Produktion AB develops vaccines and immunotherapies to prevent and treat life-threatening diseases. The company is based in Stockholm, Sweden. The Swedish company was founded by Matti Sällberg, Margaret Chen, Jens Bäck, Lars Frelin. Richard Bethell has been the CEO of the company since 2022. | Biotechnology | Chief Executive Officer | |
HARPOON THERAPEUTICS, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
NMD Pharma A/S
![]() NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | Biotechnology | Founder Director/Board Member | |
ARIX BIOSCIENCE PLC | Investment Managers | Corporate Officer/Principal Chief Executive Officer | |
Artios Pharma Ltd.
![]() Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
INITIATOR PHARMA A/S | Pharmaceuticals: Major | Founder | |
Depixus SAS
![]() Depixus SAS Miscellaneous Commercial ServicesCommercial Services Depixus SAS is a life science technology company based in Paris, France. Depixus is pioneering ground-breaking magna™ technology based on magnetic force spectroscopy, revealing dramatic new insights into complex biomolecular interactions at the single molecule level. The French company was founded by Gordon Hamilton and has been the CEO since incorporation. | Miscellaneous Commercial Services | Director/Board Member | |
Syndesi Therapeutics SA
![]() Syndesi Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium. | Miscellaneous Commercial Services | Director/Board Member | |
PYXIS ONCOLOGY, INC. | Pharmaceuticals: Major | Director/Board Member | |
Muna Therapeutics ApS
![]() Muna Therapeutics ApS Medical/Nursing ServicesHealth Services Muna Therapeutics ApS is a Danish private biopharmaceutical company that discovers and develops therapies to slow or stop neurodegenerative diseases such as Alzheimer's, frontotemporal dementia, and Parkinson's. Muna Therapeutics is based in Copenhagen, DK and was founded in 2020 by Simon Glerup and Bart de Strooper. The company focuses on identifying new medicines to preserve cognition and other brain functions and enhance resilience to these diseases. Rita Balice-Gordon has been the CEO of the company since 2020. | Medical/Nursing Services | Director/Board Member | |
Twelve Bio
![]() Twelve Bio Miscellaneous Commercial ServicesCommercial Services Part of Ensoma, Inc., Twelve Bio is a Danish company that seeks to expand the breadth of CRISPR-based gene-editing medicines to transform the management of serious diseases. The company is based in Copenhagen, Denmark. Twelve Bio uses its insights into nuclease structure and function to design highly precise and nimble CRISPR-Cas12 candidates for therapeutic application. The company will continuously advance its platform and understanding of Cas enzymes to address the needs of patients worldwide. The company was founded by Stefano Stella, Guillermo Montoya. Twelve Bio was acquired by Ensoma, Inc. on February 09, 2023. | Miscellaneous Commercial Services | Chairman | |
NRG Therapeutics Ltd.
![]() NRG Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services NRG Therapeutics Ltd. is a British neuroscience drug discovery company that focuses on building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and ALS. The company is based in Stevenage, UK, and was founded in 2018 by Neil Miller and Richard Rutter. The company's pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mptp) through a novel mechanism of action. Inhibition of the mptp has been shown to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models. Neil Miller has been the CEO since 2018. | Miscellaneous Commercial Services | Director/Board Member | |
Pheon Therapeutics Ltd.
![]() Pheon Therapeutics Ltd. BiotechnologyHealth Technology Pheon Therapeutics Ltd. is an antibody drug conjugate (ADC) specialist that develops a pipeline of monotherapies for novel targets and/or with novel payloads. The company is based in Harpdenden, UK. The British company's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. The company was founded in 2015 by Paul Jackson. Cyrus D. Mozayeni has been the CEO of the company since 2023. | Biotechnology | Director/Board Member | |
Neovii Biotech GmbH
![]() Neovii Biotech GmbH BiotechnologyHealth Technology Neovii Biotech GmbH develops and markets biopharmaceutical products in the field of transplantation. The company was founded in 2003 and is headquartered in Gräfelfing, Germany. | Biotechnology | Chief Executive Officer | |
ZYMEWORKS INC. | Pharmaceuticals: Major | Director/Board Member |
Statistieken
Internationaal
Verenigde Staten | 16 |
Verenigd Koninkrijk | 13 |
Denemarken | 8 |
Duitsland | 7 |
Zweden | 5 |
Sectoraal
Health Technology | 28 |
Consumer Services | 11 |
Commercial Services | 8 |
Finance | 5 |
Health Services | 2 |
Operationeel
Director/Board Member | 74 |
Corporate Officer/Principal | 16 |
Chief Executive Officer | 11 |
Private Equity Investor | 8 |
Founder | 8 |
Sterkste connecties
- Beurs
- Insiders
- Martin Roelsgaard Jakobsen
- Bedrijfsconnecties